Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of daclatasvir and asunaprevir combination therapy in patients with genotype 1b chronic hepatitis C patients

Trial Profile

Safety and efficacy of daclatasvir and asunaprevir combination therapy in patients with genotype 1b chronic hepatitis C patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2018

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 May 2018 New trial record
    • 14 Apr 2018 Results presented at The International Liver Congress 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top